Conference Recap: 2024 American College of Neuropsychopharmacology Annual Meeting
Key Takeaways
- The ACNP Annual Meeting focuses on psychiatry advancements, NIH priorities, and strategic research in mental health and neuropsychopharmacology.
- Discussions include alternative endpoints for substance use disorders and promising treatments for psychiatric conditions.
Catch up on coverage from the 63rd Annual Meeting of the American College of Neuropsychopharmacology in Phoenix, Arizona.
Day 1
The conference aimed at providing psychiatric clinicians with the latest in psychiatry advancements begins December 8 in Phoenix, Arizona.
An in-depth discussion with directors from key National Institutes of Health, highlighting research and strategic priorities in psychiatry, mental health, and neuropsychopharmacology.
F. Gerard Moeller, MD, discusses how complete abstinence is not the only clinically meaningful endpoint for patients with substance use disorders
Thomas R. Kosten, MD, shares insights on the ACNP meeting along with his excitement for potential new treatments.
Day 2
Stephanie Gorka, PhD, shared findings at the ACNP Annual Meeting on orexin receptor agonists addressing AUDs.
New research links reduced synaptic density,early psychosis, and cannabis use, offering insights into negative symptoms and potential interventions.
Thomas R. Kosten, MD, shares thoughts on the latest schizophrenia genetic model research presented at the meeting.
Do lifestyle interventions really work in Alzheimer disease and what are the underlying mechanisms?
Machine learning may help science better understand cognitive impairment in schizophrenia and improve prevention and patient care.
A poster at the ACNP Annual Meeting utilized a novel risk-informed case-control design to improve biomarker differentiation for ADHD.
Day 3
Data presented at ACNP meeting demonstrated safety, tolerability, and efficacy for SPN-820 for MDD.
Helen Lavretsky, MD, MS spoke about her research on how physical activity impacts older adults.
The findings of a study that observed the impact Ibogaine had on patients with mood disorder and PTSD.
Discussing research being done at Dalhousie University testing biomarker-based selection of treatment.
Newsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.
